1. No category

Pulmonary
Circulation
2015, No. 1
NEWS
April 2015
Welcome to Pulmonary Circulation News
Pulmonary Circulation’s mission is to encourage basic, translational and
clinical research by investigators, physician-scientists and clinicians in
the hope of increasing survival rates for pulmonary hypertension and
other pulmonary vascular diseases worldwide and developing new
therapeutic approaches for the diseases.
here is a tremendous need in the biomedical research community around
the globe for up-to-date, cutting edge
information on the latest research in the field
of pulmonary vascular disease. As the official
journal of the Pulmonary Vascular Research
Institute, it is our goal to provide that information as widely and as freely as possible.
T
research, interests, and hopes for the future
of PH and PVD research; as well as a conversation with our Senior Associate Editor,
Ghazwan Butrous, discussing some of the
current topics of interest in PH and PVD
research; and a spotlight on the PVRI’s
Committee for Young Clinicians &
Scientists.
It’s important to us to be the nexus of
communications for the pulmonary hypertension, pulmonary vascular disease,
and right heart failure research community of investigators, physician-scientists and
clinicians.
The journal has grown by leaps and bounds
over the four years of its existence and now,
as we enter our fifth year of publication,
we can truly say that we have gone global.
Our editorial board consists of 185
internationally-recognized experts from
countries all across the globe, and, in the
past year alone, we have had manuscript
submissions from authors from Asia,
Africa, Europe, the Middle East, North
and South America, and Australia.
To that end, we will be sending this newsletter out on a quarterly basis, with useful,
targeted updates for professionals in the
field of PVD research. It is our hope to
engage or otherwise involve our readers,
perhaps even to spark discussion or debate,
two of the most important driving forces
of discovery.
Examples of what you’ll see in Pulmonary
Circulation News include announcements,
featured articles from the journal, the table
of contents of the latest journal issue, interviews with featured PC Editorial Board
members, current topics of research, news
from young scientists, lists of pulmonary
hypertension programs, a calendar of events
related to PVD, calls for submissions, and
more.
In this issue of Pulmonary Circulation News
you will find an interview with PC Editorial
Board member, Larissa Shimoda, on her
If you have any thoughts, ideas, or suggestions concerning Pulmonary Circulation, or
would like to submit a “Reader’s Comment”
to appear in the next issue of Pulmonary
Circulation News, please contact Annisa
Westcott at [email protected].
Editorial Board
Editors-in-Chief:
Jason X.-J. Yuan, MD, PhD
Nicholas W. Morrell, MD
Senior Associate Editor:
Ghazwan Butrous, MD
Managing Editor
and PC News Editor:
Annisa Westcott, BA
Associate Editors:
Stephen L. Archer, MD
Candice D. Fike, MD
Joe G.N. Garcia, MD
Hossein A. Ghofrani, MD
Sheila G. Haworth, MD
Antonio A. Lopes, MD
Marlene Rabinovitch, MD
Stuart Rich, MD
Werner Seeger, MD
Kurt R. Stenmark, MD
Patricia A. Thistlethwaite, MD, PhD
Chen Wang, MD, PhD
Martin R. Wilkins, MD
Scientific Advisory Board:
Robert F. Grover, MD, PhD
Charles A. Hales, MD, PhD
Joseph Loscalzo, MD
E. Kenneth Weir, MD
John B. West, MD, PhD, DSc
Magdi H. Yacoub, MD, DSc, FRS
In This Issue
Welcome . . . . . . . . . . . . . . . . . . . 1
Journal Office News . . . . . . . . . . . 2
PH Care and Research Centers . . . 2
Journal Table of Contents . . . . . . . 3
Call for Submissions . . . . . . . . . . 4
Featured Articles . . . . . . . . . . . . . 5
Researcher Spotlight . . . . . . . . . . 6
Current Topics . . . . . . . . . . . . . . . 7
Spotlight on the PVRI . . . . . . . . . . 8
Calendar of Events . . . . . . . . . . . . 8
PVRI Task Forces . . . . . . . . . . . . . 9
1
Journal Office News
Our “New” Office and Staff
In May of 2014, Dr. Jason X.-J. Yuan, Editor-in-Chief, accepted a position as Associate Vice President for Translational Health Sciences at the University of Arizona. The Editorial Office of Pulmonary Circulation was relocated from Chicago,
Illinois to Tucson, Arizona with him. At the beginning of July, 2014, Annisa Westcott joined Pulmonary Circulation as the new Managing Editor. Annisa is a native of
Tucson, where she graduated from the University of Arizona, Magna Cum Laude,
with dual BAs in Linguistics and English. A polyglot, Annisa has studied Italian,
Spanish, Modern Greek, and Latin.
On The Web
You may have noticed that PC and PVRI’s websites are changing. One of the
important initiatives that PC and PVRI are working on this year is improving our
websites. Our goal is to be the anchor-point of the pulmonary vascular disease
research community and one of the most important ways in which we can do that
is to provide an online landing site and clearinghouse for information related to the
field. We have many more improvements planned. For further news on our progress
please visit www.pulmonarycirculation.org or www.pvri.info.
Publication Fees
A note about open access and author publication fees: In order for us to be able to
continue to provide our readers with free open access to all of our journal articles
we have, with the advice of our publisher, made the decision to begin in 2015 to ask
our authors to pay a publication fee. These fees were instituted beginning January 1, 2015, for all new submissions received on or after
that date. For Original Research articles and Guidelines articles, the publication fee is now $1,000. For a traditional Case Report (up to
1,000 words), the fee is $500, and for an Extended Case Report (up to 2,500 words), the fee is $750. Invited Review articles will not be
charged a publication fee.
PH Care and Research Centers
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has recently funded a multicenter program to redefine pulmonary hypertension through genomics, proteomics and phenomics. The program includes
one Data Coordinating Center and six Clinical Centers:
Data Coordinating Center:
Cleveland Clinic Foundation, Cleveland, OH (Principal Investigators:
Gerald J. Beck, PhD and Serpil C. Erzurum, MD)
Clinical Centers:
Brigham and Women’s Hospital, Boston, MA (Principal Investigators:
Jane A. Leopold, MD and Aaron B. Waxman, MD, PhD)
Columbia University and Cornell University, New York, NY (Principal Investigators: Erika S. Berman Rosenzweig, MD and Evelyn M. Horn, MD)
Mayo Clinic, Rochester, MN (Principal Investigator: Robert P. Frantz,
MD)
University of Arizona, Tucson, AZ (Principal Investigators: Franz
Rischard, DO and Jason X.-J. Yuan, MD, PhD)
Vanderbilt University, Nashville, TN (Principal Investigators: John
Newman, MD and Anna Hemnes, MD)
Johns Hopkins University, Baltimore, MD (Principal Investigators: Paul
Hassoun, MD and Stephen Mathai, MD)
2
Pulmonary Circulation
Volume 5 / Number 1 / March 2015
Published by The University of Chicago
Press on behalf of the Pulmonary
Vascular Research Institute (PVRI)
Read the full issue online at:
http://www.jstor.org/stable/10.1086/679629
Editorial
The rise and rise of Pulmonary Circulation
Jason X.-J. Yuan, Nicholas W. Morrell, Annisa Westcott, and
Ghazwan Butrous
Stable URL: http://www.jstor.org/stable/10.1086/680857
Review Articles
The right ventricle in scleroderma (2013 Grover Conference
Series)
Paul M. Hassoun
Stable URL: http://www.jstor.org/stable/10.1086/679607
Cardiac energy metabolic alterations in pressure overload–induced left and right heart failure (2013 Grover Conference
Series)
Sowndramalingam Sankaralingam and Gary D. Lopaschuk
Stable URL: http://www.jstor.org/stable/10.1086/679608
The right ventricle under pressure: evaluating the adaptive and
maladaptive changes in the right ventricle in pulmonary arterial
hypertension using echocardiography (2013 Grover Conference
series)
Alexis Harrison, Nathan Hatton, and John J. Ryan
Stable URL: http://www.jstor.org/stable/10.1086/679699
Neonatal oxygenation, pulmonary hypertension, and evolutionary adaptation to high altitude (2013 Grover Conference series)
Susan Niermeyer, Mario Patricio Andrade-M, Enrique Vargas, and
Lorna G. Moore
Stable URL: http://www.jstor.org/stable/10.1086/679719
Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series)
Maria A. Cavasin, Kurt R. Stenmark, and Timothy A. McKinsey
Stable URL: http://www.jstor.org/stable/10.1086/679700
Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference
Series)
Arnoud van der Laarse, Christa M. Cobbaert, and Soban Umar
Stable URL: http://www.jstor.org/stable/10.1086/679701
The need to recognize the pulmonary circulation and the right
ventricle as an integrated functional unit: facts and hypotheses
(2013 Grover Conference series)
Norbert F. Voelkel, Harm Jan Bogaard, and Jose Gomez-Arroyo
Stable URL: http://www.jstor.org/stable/10.1086/679702 Original Research
The role of wall shear stress in the assessment of right ventricle hydraulic workload
Vitaly Kheyfets, Mirunalini Thirugnanasambandam, Lourdes Rios,
Daniel Evans, Triston Smith, Theodore Schroeder, Jeffrey Mueller,
Srinivas Murali, David Lasorda, Jennifer Spotti, and Ender Finol
Stable URL: http://www.jstor.org/stable/10.1086/679703
Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension
Ayser Al-Husseini, Donatas Kraskauskas, Eleanora Mezzaroma,
Andrea Nordio, Daniela Farkas, Jennifer I. Drake, Antonio Abbate,
Quentin Felty, and Norbert F. Voelkel
Stable URL: http://www.jstor.org/stable/10.1086/679704
Impact of diabetes in patients with pulmonary hypertension
Abraham D. Abernethy, Kathryn Stackhouse, Stephen Hart, Ganesh
Devendra, Thomas M. Bashore, Raed Dweik, and Richard A. Krasuski
Stable URL: http://www.jstor.org/stable/10.1086/679705
Arginine metabolic endotypes in pulmonary arterial hypertension
Christina C. Kao, Samuel H. Wedes, Jean W. Hsu, Kurt M. Bohren,
Suzy A. A. Comhair, Farook Jahoor, and Serpil C. Erzurum
Stable URL: http://www.jstor.org/stable/10.1086/679720
Right ventricular long noncoding RNA expression in human
heart failure
Thomas G. Di Salvo, Yan Guo, Yan Ru Su, Travis Clark, Evan Brittain,
Tarek Absi, Simon Maltais, and Anna Hemnes
Stable URL: http://www.jstor.org/stable/10.1086/679721
Acute hemodynamic effects of nebulized iloprost via the I-neb
Adaptive Aerosol Delivery system in pulmonary hypertension
Manuel J. Richter, Hossein A. Ghofrani, Robert Voswinckel, Werner
Seeger, Richard Schulz, Frank Reichenberger, and Henning Gall
Stable URL: http://www.jstor.org/stable/10.1086/679722
Derivation of a screening tool to identify patients with right
ventricular dysfunction or tricuspid regurgitation after negative
computerized tomographic pulmonary angiography of the chest
Jeffrey A. Kline, Frances M. Russell, Tim Lahm, and Ronald A. Mastouri
Stable URL: http://www.jstor.org/stable/10.1086/679723
The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype
Olga Rafikova, Ruslan Rafikov, Mary Louise Meadows, Archana
Kangath, Danny Jonigk, and Stephen M. Black
Stable URL: http://www.jstor.org/stable/10.1086/679724
Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled
iloprost
Nicole L. Grossman, Christopher A. Fiack, Janice M. Weinberg, Denis
V. Rybin, and Harrison W. Farber
Stable URL: http://www.jstor.org/stable/10.1086/679725
Peripheral pulmonary artery stenosis as a cause of pulmonary
hypertension in adults
Adriano R. Tonelli, Mostafa Ahmed, Fadi Hamed, and Lourdes R. Prieto
Stable URL: http://www.jstor.org/stable/10.1086/679727
Case Report
Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature
Wayne L. Feyereisn, Eric R. Fenstad, Robert B. McCully, and Martha Q. Lacy
Stable URL: http://www.jstor.org/stable/10.1086/679726
Obituary
Kenneth D. Bloch, MD (1956–2014)
Fumito Ichinose and Warren M. Zapol
Stable URL: http://www.jstor.org/stable/10.1086/680856
3
Call for Submissions
The first journal devoted
exclusively to the field of
the pulmonary circulation
Editors-in-Chief:
Jason X.-J. Yuan, MD, PhD and
Nicholas W. Morrell, MD
Pulmonary Circulation, official journal of the Pulmonary Vascular Research Institute, is an international, peer-reviewed
medical research journal focused on publishing original research, review articles, case reports, and guidelines and consensus articles exclusively in the fields of the pulmonary circulation and pulmonary vascular disease.
Pulmonary Circulation’s main goal is to encourage basic, translational and clinical research by investigators, physician-scientists and clinicians in the hope of increasing survival rates for pulmonary hypertension and other pulmonary
vascular diseases worldwide and developing new therapeutic approaches for the diseases.
Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a
wide readership of specialists in order to improve patient care and treatment outcomes.
To read the journal, submit an article, or find out more, visit:
journals.uchicago.edu/PC
4
Spotlight on the Journal
Featured Articles
RV and LV MPRIs in control, non-PAH, and PAH groups.
The right ventricle in scleroderma (2013 Grover Conference Series)
Paul M. Hassoun
March 2015, Vol. 5, No. 1: 3-14.
Stable URL: http://www.jstor.org/stable/10.1086/679607
From the Abstract:
Pulmonary arterial hypertension (PAH) results from severe remodeling of the distal
lung vessels leading irremediably to death through right ventricular (RV) failure. PAH
(Group 1 of the World Classification of pulmonary hypertension) can be idiopathic
(IPAH) or associated with other disorders such as connective tissue diseases. Prominent
among the latter is systemic sclerosis (SSc), a heterogeneous disorder characterized
by endothelium dysfunction, dysregulation of fibroblasts resulting in excessive
collagen production, and immune abnormalities. For as yet unknown reasons,
SSc-associated PAH (SSc-PAH) carries a significantly worse prognosis compared to
any other form of PAH in Group 1 including IPAH.
Right ventricular long noncoding RNA expression
in human heart failure
Thomas G. Di Salvo, Yan Guo, Yan Ru Su, Travis Clark, Evan Brittain,
Tarek Absi, Simon Maltais, and Anna Hemnes
March 2015, Vol. 5, No. 1: 135-161.
Stable URL: http://www.jstor.org/stable/10.1086/679721
From the Introduction:
lncRNA Secondary Structure
The results reported from ENCODE are transforming our nascent understanding of integrated human genomics. Fully 75% of the human genome
is transcribed into some type of RNA although only 1.22% of the genome
encodes the exons that comprise the 20,687 known protein-coding
genes. The vast majority of the human genome, therefore, is transcribed
into non-protein coding RNAs, including the 8,801 small RNAs, 9,640
long non-coding (lnc) RNAs and 11,224 pseudogenes identified to date.
Evolving research has identified diverse epigenetic regulatory roles for
lncRNAs in development, homeostasis and disease. lncRNAs are likely to
play important regulatory roles in human heart failure as well.
5
Researcher Spotlight
An Interview with
Larissa A. Shimoda, Ph.D.,
Associate Professor,
Johns Hopkins University
School of Medicine
D
r. Shimoda is an Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at Johns Hopkins
University School of Medicine in Baltimore, Maryland. She began there as a Fellow in 1995 and joined the faculty in 1998. She is
also a member of the Pulmonary Circulation Editorial Board.
PC: What is your area of research?
LS: I am a basic scientist and my work focuses on the cellular mechanisms involved in the development of pulmonary hypertension. We
use a combination of in vivo and in vitro approaches, including animal models and cells from patients.
PC: What project(s) are you currently involved in?
LS: I have had a long-standing interest in identifying the role of membrane channels and transporters in regulating pulmonary vascular
smooth muscle function and determining how changes in the expression/activity of these channels cause abnormalities in cell contraction, growth and migration. Recently, we have identified non-traditional roles for several of these proteins in controlling pulmonary
vascular cell growth that are separate from transport function. To me, this is of interest because these channels have important roles
throughout the body in maintaining normal cellular homeostasis, so being able to selectively target a function that is independent of their
normal transport properties opens the door to development of therapeutics with reduced side effects.
PC: What interested you in pulmonary hypertension and PVD?
LS: As a graduate student, I was studying regulation of vasomotor tone by blood flow. I had found that increasing blood flow in an
isolated pulmonary artery caused the production and release of the vasoconstrictor, endothelin-1. As I was starting my fellowship training, the first reports demonstrating that endothelin-1 contributed to pulmonary hypertension in animal models were published. I found
the potential link between my studies and a clinically important disease fascinating, and I was hooked!
“Understanding the changes in cell metabolism that allow for
enhanced growth and resistance to cell death will be critical in
targeting pulmonary vascular remodeling.”
PC: To you, what is the most exciting area of PVD research?
LS: There are several exciting areas of research emerging in pulmonary vascular disease. Research in epigenetics and microRNAs is likely
to provide novel insights into the genetic regulation of disease pathogenesis. Cellular bioenergetics is another exciting area. Understanding the changes in cell metabolism that allow for enhanced growth and/or resistance to cell death will be critical in targeting pulmonary
vascular remodeling.
PC: Where do you hope to see the field of pulmonary hypertension or PVD research in five years?
LS: While we have made tremendous progress thus far, I would hope that in 5 years we will have a better understanding of the factors
that contribute to disease pathogenesis and progression, which will spur development of new therapeutics to slow and, perhaps even more
importantly, reverse pulmonary hypertension. In addition, as we achieve a better understanding of the genetic basis of the disease, the
goal of tailoring therapy to match each patient’s specific genotype/phenotype may become more of a possibility.
6
Spotlight on Current Topics
A Conversation with Ghazwan Butrous, M.D.
Senior Associate Editor, Pulmonary Circulation
Annisa Westcott, Managing Editor
AW: Dr. Butrous, thank you for speaking with me today. Could you please tell me what, in your opinion, are some of the most important
current topics in the research field of pulmonary circulation, pulmonary vascular pathobiology, and pulmonary vascular disease?
GB: The subject of pulmonary vascular disease is a very broad subject. It is not one disease but a series of different diseases. The end result
is usually the same, i.e. increased pulmonary pressure, but the primary cause varies so widely, to the extent that the pathobiology is very
vast. To me, studying molecular biology and signaling mechanisms is very important, and in particular, the current increase in the interest
in epigenetics will open new dimensions for the understanding of the molecular signaling mechanisms and the proper understanding
of the pathobiological process. So epigenetics, for the time being, if you ask me, is the most important current topic in the research field
of pulmonary circulation, which can eventually lead to new or novel approaches in the management of pulmonary vascular diseases and
pulmonary hypertension. Other important current topics are the differentiation of the various primary causes like hypoxia, the role of the
pathological process in chronic obstructive lung diseases, the role of inflammation, and the mechanical effects of heart failure, to name
a few.
AW: It is a very complex puzzle, to be sure! Obviously, due to the complex nature of this series of diseases, there is no one-size-fits-all
treatment, and, as I understand it, much research remains to be done before we find a cure. As it stands today, what is the most important
advancement, in your opinion, in the current treatment and prevention of pulmonary hypertension/pulmonary vascular pathobiology,
and right heart dysfunction or failure associated with pulmonary hypertension?
GB: To be honest, none of the current therapies which have been established over the last 15 years are the final answer to the management of pulmonary hypertension or pulmonary vascular disease. They constitute the right and the first step toward further understanding
of the management of pulmonary hypertension, and they have made a lot of difference, particularly in increasing the awareness of this
condition among physicians, which eventually has led to the improvement in prognosis of patients. Let me explain. In the past before
the current therapeutic approach, we tended not to diagnose PH or even to think about it clinically, thus leading to misdiagnoses and
eventually to seeing patients only in the very advanced stages of disease. Now, because of the presence of these drugs, treatment begins
much earlier than before, resulting in the improvement in prognosis for patients.
However, one unintended and unfortunate consequence of the introduction of these drugs, is an overall slow-down of innovation in
the field because we tend to do clinical trials only for add-ons, instead of new, novel approaches. What the field needs are new ways of
thinking and innovative approaches in clinical investigations and trials.
AW: What do you think is the best way to address these topics?
GB: Pulmonary vascular disease is a very diverse series of conditions, even within a specific category, and thus one center’s studies may
not be the final answer; this consequently necessitates the need for collaborative work, which should be a hallmark of the nature of research in PVD. We definitely, therefore, need open, cross-center discussions and collaborations if we are really serious about broadening
and deepening our knowledge base about these diseases.
We also need to be open minded and not be too dependent on current ways of thinking. We have somewhat imprisoned ourselves into
the realm of current classification, which does not well serve the pathobiology, the investigation, the clinical picture, or the therapeutic
approach to the condition, because of what I mentioned before, the broad diversity of the primary and final causes of PH.
AW: How can Pulmonary Circulation and the PVRI help in order to move these forward?
GB: Further to what I mentioned above, we would very much like Pulmonary Circulation and the PVRI meetings to serve as a forum for
scientific discussion and debate, helping to move the science back into the realm of discourse and discovery and out of the confines of
the printed page. A good debate can stimulate further thinking and enhance controversy, thus returning us to the universality of scientific
communication. Let’s not forget that this year we are celebrating 350 years since the publication of the first “modern” scientific journal,
Philosophical Transactions, which was first published in 1665, by the Royal Society. If we examine the first issues of that journal, we will
notice that it did not publish only positive results or papers, but scientific debates and controversies that have helped scientists in their
work in the further exploration of knowledge, and thus contributed significantly to the scientific advances and research which moved the
scientific revolution forward, and the results of which we enjoy today.
7
Spotlight on The PVRI
The PVRI’s Committee for Young
Clinicians & Scientists (CYCS)
functions as the PVRI’s “right
ventricle” in changing times
Michiel Alexander de Raaf (M.Sc., B.A.Sc., FPVRI),
Michael Seimetz (M.Sc., PhD, FPVRI), Djuro Kosanovic (M.Sc., PhD, FPVRI)
I
n response to alterations in the pulmonary vasculature, the right ventricle remodels
itself to meet the needs of the system. In times of change, in scientific organizations
such as the PVRI, things are not very different. The PVRI organization continuously
responds to the propelling speed of scientific development, encouraging innovation and
new opportunities to push our field further toward its goal of increasing the quality of
patient life. Within the PVRI, the Committee for Young Clinicians & Scientists (CYCS)
is a platform for researchers and medical doctors who wish to actively contribute to the
development of the PVRI by supporting its other committees in responding to changes in
the field, thus earning us our nickname, the ‘Active Support Committee’.
The core activities of the CYCS focus on education through publishing our journal, the
PVRI Chronicle; recording lectures and interviews from experts in the field; and
working backstage during conferences to record the sessions and keep the program running
smoothly. All of this educational content can be found at www.pvri.info/learning. At this
moment, our PVRI learning website already contains over 650 educational files.
With the transition to a new PVRI logo and website, it is time to re-evaluate all
interviews, lectures and recorded sessions for their scientific and technical quality. In the
coming months you will find an updated inventory of enhanced-quality videos on the
website.
It is a delight to announce that the work of our members was recognized by the PVRI at the
recent 8th Annual PVRI World Congress in Guangzhou, China, where we were presented
with the PVRI Certificate of Excellence. This recognition was a very high honor for us,
but whether we receive awards for our service or not, we remain highly motivated to
continue supplying dedicated support to the PVRI and its other committees. If you are
interested in learning more about our committee or becoming involved, please send an
e-mail to the CYCS-secretary: [email protected].
Contact Us
Questions? Concerns?
Comments? Suggestions?
We want to hear from you!
Pulmonary Circulation
Editorial Office
1656 East Mabel Avenue
PO Box 245215
Tucson, AZ 85724, USA
Phone: (520) 626-8350
Fax: (520) 626-7400
Email: [email protected]
Calendar of Events
April 9-11, 2015
8th Annual Meeting of the Saudi
Association for Pulmonary
Hypertension (SAPH)
http://www.saph2015.com/
May 5, 2015
World PH Day
http://www.worldphday.org/
May 15-20, 2015
Annual Meeting of the American
Thoracic Society (ATS)
http://conference.thoracic.org/2015/
June 8-9, 2015
2nd Annual Drug Discovery and
Development (DDD) Symposium
http://pvri.info/londonmeeting2015
Have an event you’d like to see on
our calendar? Contact us and we
will be happy to list your event in
future issues of Pulmonary Circulation News. Send an email to
[email protected].
Photo: 7th PVRI Annual General Meeting,
Istanbul, 2013
8
Interested in The PVRI?
Let’s get together in Denver
Drs. Kurt Stenmark and Stephen Archer,
PVRI North America Task Force Leaders,
warmly invite you to this year’s ‘PVRI
Get-Together’ during the American Thoracic Society’s ATS 2015 International
Conference in Denver. The ‘Get-Together’ will be held on Tuesday 19th May
2015 from 6-8pm on the sundeck of the
Denver Athletic Club, which is located
close to the ATS conference venue. A selection of drinks and pre-dinner canapés
will be provided courtesy of the PVRI.
Who should attend?
All PVRI members who will attend the ATS
meeting in May 2015 and their guests.
Please bring along anyone else who is interested in finding out more about the PVRI.
What’s the purpose of the meeting?
A social gathering to mix and mingle and
spread the word about the PVRI to new
potential members.
Is there a cost?
No, all you need to do is ‘register’, so we
have a rough idea of numbers.
RSVP: http://pvri.info/content/pvri-denver-get-together
PVRI Task Forces
Join us and help shape our future
Regional Task Forces
- Latin America
- Saudi Association for Pulmonary Hypertension and EMR (Eastern Mediterranean
Region)
- Southeast Asia
- Central Asia
- Sub-Saharan Region
- China
- Europe
- North America
- Paediatric Task Force
We believe in collaboration. Our global
membership network includes over 800
clinicians and scientists from 60 different
countries. We have established Regional
and Specialty Task Forces all over the
world to raise awareness of the disease
and to facilitate research. Twice a year,
we organise large scientific meetings on
different continents to bring together our
members, the pharmaceutical industry and
the drug regulatory bodies to work toward
finding better solutions for PVD sufferers.
Disease and Specialty Task Forces
-
Paediatric Task Force
Exercise
High Altitude & Hypoxia
Schistosomiasis
Congenital Heart Disease
Women’s Health and Pregnancy
Right Heart Failure
PH associated with HIV
Genes, Molecules and Drug Discovery
Committee for Young Clinicians and
Scientists
For more information, please visit
http://pvri.info/content/join-task-forceand-shape-our-future
Is it important that I attend?
Yes! The PVRI as an organization works
because of global collaboration. The
principle of collaboration is the cornerstone of what we do and meeting in a
scientific or social context is important
for all our members and those who want
to find out more about the PVRI.
Got Social?
Are you on social media? So are
we! Help us reach 100 likes on
Facebook! Follow us on Twitter for
relevant news and journal updates.
facebook.com/PulmonaryCirculation
twitter.com/PulmCirc
Click here to “like” us on Facebook
And here to follow us on Twitter!
9
10